Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-03 · accession 0001725160-22-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-05 | 2022-01-03 | ZNTL | Blackwell Kimberly | Dir | S - Sale+OE | $83.74 | -1,000 | 5,000 | -17% | -$83.7K |
| D | 2022-01-05 | 2022-01-03 | ZNTL | Blackwell Kimberly | Dir | M - OptEx | $47.80 | +1,000 | 6,000 | +20% | +$47.8K |
| D | 2022-01-05 | 2022-01-03 | ZNTL | Blackwell Kimberly | Dir | M - OptEx | $0.00 | -1,000 | 38.0K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | S | D | 1,000 | $83.74 | 5,000 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-03 | M | A | 1,000 | $47.80 | 6,000 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-01-03 | M | D | 1,000 | $0.00 | 38,000 | D | $47.80 · — to 2030-06-30 | 1,000 Common Stock | (F2) The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant on July 1, 2020. |